Evidence map›Paper›PMID 39911316›Full record

ArticlePNAS nexus2025

Selective inhibitors of the TrkC.T1 receptor reduce retinal inflammation and delay neuronal death in a model of retinitis pigmentosa.

Fouad Brahimi, Hassan Nassour, Alba Galan, Revathy Guruswamy, Christina Ortiz, Ali Nejatie, Hinyu Nedev, Jean-Francois Trempe, H Uri Saragovi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PNAS nexus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Fouad BrahimiLady Davis Institute-Jewish General Hospital, McGill University, Center for Translational Research, Montreal, QC, Canada H3T 1E2.ORCID https://orcid.org/0000-0001-6231-2091
Hassan NassourLady Davis Institute-Jewish General Hospital, McGill University, Center for Translational Research, Montreal, QC, Canada H3T 1E2.ORCID https://orcid.org/0009-0007-4353-0246
Alba GalanLady Davis Institute-Jewish General Hospital, McGill University, Center for Translational Research, Montreal, QC, Canada H3T 1E2.
Revathy GuruswamyPharmacology and Therapeutics, McGill University, Montreal, QC, Canada H3G 1Y6.ORCID https://orcid.org/0009-0002-5780-3261
Christina OrtizLady Davis Institute-Jewish General Hospital, McGill University, Center for Translational Research, Montreal, QC, Canada H3T 1E2.
Ali NejatieLady Davis Institute-Jewish General Hospital, McGill University, Center for Translational Research, Montreal, QC, Canada H3T 1E2.ORCID https://orcid.org/0000-0001-8187-4831
Hinyu NedevLady Davis Institute-Jewish General Hospital, McGill University, Center for Translational Research, Montreal, QC, Canada H3T 1E2.
Jean-Francois TrempePharmacology and Therapeutics, McGill University, Montreal, QC, Canada H3G 1Y6.ORCID https://orcid.org/0000-0002-6543-3371
H Uri SaragoviLady Davis Institute-Jewish General Hospital, McGill University, Center for Translational Research, Montreal, QC, Canada H3T 1E2.ORCID https://orcid.org/0000-0001-6884-8815

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The heterogeneity of receptor isoforms can cause an apparent paradox where each isoform can promote different or even opposite biological pathways. One example is the neurotrophin receptor TrkC. The

Indexed as

chemical biologyneuroprotectionneurotoxicityphotoreceptorTrkC receptor isoform

Identifiers

PMID39911316
PMCPMC11795507

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.